Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CareRx's Enterprise Value is €168.7 Mil.
CareRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €7.1 Mil. Therefore, CareRx's EV-to-EBIT for today is 23.88.
The historical rank and industry rank for CareRx's EV-to-EBIT or its related term are showing as below:
FRA:29C1'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1198.96 Med: -5.96 Max: 120.87
Current: 23.95
During the past 13 years, the highest EV-to-EBIT of CareRx was 120.87. The lowest was -1198.96. And the median was -5.96.
FRA:29C1's EV-to-EBIT is ranked worse than 70.86% of 477
companies
in the Healthcare Providers & Services industry
Industry Median: 15.75
vs FRA:29C1: 23.95
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CareRx's Enterprise Value for the quarter that ended in Jun. 2026 was €173.3 Mil.
CareRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareRx EV-to-EBIT Related Terms
CareRx EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for CareRx's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, CareRx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareRx EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CareRx's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CareRx's EV-to-EBIT falls into.
CareRx's current Enterprise Value is €168.7 Mil.
CareRx's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CareRx (FRA:29C1) has a EV-to-EBIT of 23.88 as of Aug. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CareRx and its competitors. According to the industry distribution chart, CareRx ranks #338 out of 477 companies in the Healthcare Providers & Services industry, placing it in the top 70.9%.
Is CareRx's EV-to-EBIT too high?
CareRx's current EV-to-EBIT is 23.88. The Healthcare Providers & Services industry median EV-to-EBIT is 15.75. CareRx's value of 23.88 is 51.6% above this industry median. Based on the distribution chart, CareRx ranks #338 out of 477 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, CareRx has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's EV-to-EBIT compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #338 out of 477 companies for EV-to-EBIT. This places CareRx in the lower half of its industry. The industry median EV-to-EBIT is 15.75. CareRx's value of 23.88 is 51.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.75, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareRx's current EV-to-EBIT of 23.88 is 51.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current EV-to-EBIT is 23.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current EV-to-EBIT of 23.88. The stock's GF Value™ is €1.47, compared to a current price of €1.95 — trading 32.7% above its estimated fair value. The current EV-to-EBIT is 23.88 and 51.6% above the Healthcare Providers & Services industry median of 15.75. CareRx's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For CareRx (FRA:29C1), the current EV-to-EBIT is 23.88 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €1.95 is trading 32.7% above its estimated GF Value™ of €1.47.
Key valuation signals for FRA:29C1:
EV-to-EBIT: 23.88
GF Value™: €1.47 vs. price of €1.95 (32.7% above fair value)
Industry Position: 51.6% above the Healthcare Providers & Services median (#338 of 477)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
65GF Score
Get the complete analysis for FRA:29C1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
